Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City
Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis o...
Saved in:
Published in | Japanese Journal of Infectious Diseases Vol. 74; no. 4; pp. 307 - 315 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Japan
National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
31.07.2021
Japan Science and Technology Agency |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60–1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use. |
---|---|
AbstractList | Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60–1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use. Since cytokine release syndrome is considered to be associated with severe cases of COVID-19, steroids are expected to be effective for its treatment. We aimed to investigate the use of steroids and its impact. We conducted a retrospective chart review and analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse weighted probability weighted analysis was performed to assess the effect of steroids for in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease than no steroid group and also had higher lactate dehydrogenase, d-dimer, and inflammatory makers compared to no steroid group (all P<0.05). The steroid group had significantly higher rates of multifocal pneumonia than no steroid group at admission (75.4% versus 50.3%, P=0.001). Notably, steroid group had higher rates of bacterial infection (25% versus 13.1%, P=0.041) and fungal infection (12.7% versus 0.7%, P<0.001) during hospital course. After adjustment, steroid did not decrease or increase in-hospital mortality (OR [95% CI]: 1.02 [0.60-1.73, P=0.94]). Steroid did not decrease the in-hospital mortality rate. There were increased bacterial and fungal infections with steroid use. Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60-1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use.Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60-1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use. |
ArticleNumber | JJID.2020.884 |
Author | Maeda, Tetsuro Kuno, Toshiki Rizk, Dahlia Obata, Reiichiro |
Author_xml | – sequence: 1 fullname: Obata, Reiichiro organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA – sequence: 2 fullname: Maeda, Tetsuro organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA – sequence: 3 fullname: Rizk, Dahlia organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA – sequence: 4 fullname: Kuno, Toshiki organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33390434$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtr3DAURkVJaZ6_oFAM3XTjqeQry_KyTPpwCE0hD8hKaOTrRhOPlEgawvz7yp1JoFl0o6vFOZfL9x2SPecdEvKe0VkjJXze-Ht0s7Oz7nRW0YrOpORvyAHLo6wkiL38B85LAZTvk8MYl5RWdc3oO7IPAC3lwA_IbedMQB2xLy7ReNfrsCk6N6BJ1rvCumJ-cdOdlqwtfulk0aVYXGUhZeHJprviMmHwto8T-hOfilsf7ou5TZtj8nbQY8ST3Twi19--Xs1_lOcX37v5l_PS1MBTOYjBCFMxHIwedCuQC7ngRlTAGCxM29YCepRCD5zKfgEtA9FIQRtDa9YIgCPyabv3IfjHNcakVjYaHEft0K-jqnhTU9nQlmb04yt06dfB5etUTqapBGWcZerDjlovVtirh2BXORX1HFoG2i1ggo8x4KCMTXrKKwVtR8WomgpSfwtSU0FqKkjlZrILr9zn9f-3uq21jEn_xhdHh2TNiDun4YpPzz_uC2PudFDo4A_KqK27 |
CitedBy_id | crossref_primary_10_1164_rccm_202110_2317LE crossref_primary_10_1016_j_cmi_2021_11_008 crossref_primary_10_1038_s41590_021_01091_0 crossref_primary_10_1016_j_intimp_2021_108384 crossref_primary_10_2217_fvl_2021_0244 crossref_primary_10_3390_microorganisms10122372 crossref_primary_10_1097_JCMA_0000000000000764 crossref_primary_10_1183_13993003_03222_2021 crossref_primary_10_21292_2078_5658_2021_18_6_15_21 crossref_primary_10_33073_pjm_2021_039 crossref_primary_10_2478_jccm_2022_0025 crossref_primary_10_17352_2455_5282_000148 crossref_primary_10_3390_ijms241914800 crossref_primary_10_1016_j_idcr_2022_e01656 crossref_primary_10_3390_jcm11072017 crossref_primary_10_1007_s11739_021_02824_7 crossref_primary_10_1016_S2666_5247_22_00355_X crossref_primary_10_1186_s13018_024_04556_8 crossref_primary_10_7759_cureus_17178 crossref_primary_10_1111_myc_13292 crossref_primary_10_1186_s43162_023_00215_2 crossref_primary_10_2174_2772434417666220720122042 crossref_primary_10_1017_ash_2022_253 crossref_primary_10_3390_jof7110921 crossref_primary_10_3390_life13040907 crossref_primary_10_1002_ccr3_6103 crossref_primary_10_1002_jmv_27393 crossref_primary_10_1016_j_isci_2024_110218 crossref_primary_10_1007_s10157_021_02126_4 crossref_primary_10_3390_antibiotics11081016 crossref_primary_10_1002_phar_2637 crossref_primary_10_4103_ecdt_ecdt_3_22 crossref_primary_10_1186_s43055_022_00700_8 crossref_primary_10_1007_s11239_021_02569_2 crossref_primary_10_1002_jmv_27421 crossref_primary_10_3390_v15091934 crossref_primary_10_37990_medr_1527943 crossref_primary_10_7759_cureus_41054 crossref_primary_10_1371_journal_pone_0309392 crossref_primary_10_3390_biom12050690 crossref_primary_10_4103_ijpm_ijpm_141_22 |
Cites_doi | 10.1001/jama.2020.5394 10.1016/S0140-6736(20)30566-3 10.1136/bmj.m606 10.1164/rccm.201706-1172OC 10.1016/S0140-6736(20)30183-5 10.1001/jamainternmed.2020.0994 10.1001/jama.2016.0287 10.1001/jama.2020.16761 10.1002/jmv.25948 10.1136/bmj.m2426 10.2215/CJN.10181014 10.1056/NEJMcp2009575 10.1056/NEJMoa2021436 10.1136/bmj.m1333 10.1038/s41392-020-0127-9 10.1093/eurheartj/ehaa035 10.1016/j.ijantimicag.2020.105949 10.1136/annrheumdis-2020-217523 10.1056/NEJMoa2001017 10.1001/jama.2020.17021 10.1016/j.cmi.2020.04.040 10.1056/NEJMp1213844 10.1093/cid/ciaa478 10.1016/S0140-6736(20)30317-2 |
ContentType | Journal Article |
Copyright | 2021 Authors Copyright Japan Science and Technology Agency 2021 |
Copyright_xml | – notice: 2021 Authors – notice: Copyright Japan Science and Technology Agency 2021 |
DBID | AAYXX CITATION NPM 7QL 7T5 7T7 7TK 7U9 8FD C1K FR3 H94 M7N P64 7X8 |
DOI | 10.7883/yoken.JJID.2020.884 |
DatabaseName | CrossRef PubMed Bacteriology Abstracts (Microbiology B) Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Virology and AIDS Abstracts PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1884-2836 |
EndPage | 315 |
ExternalDocumentID | 33390434 10_7883_yoken_JJID_2020_884 article_yoken_74_4_74_JJID_2020_884_article_char_en |
Genre | Journal Article |
GeographicLocations | United States--US New York City New York |
GeographicLocations_xml | – name: New York City New York – name: United States--US |
GroupedDBID | --- .55 29J 2WC 53G 5GY ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL DIK DU5 E3Z EBS EJD F5P FRP GX1 JSF JSH KQ8 OK1 RJT RNS RZJ TR2 W2D X7M XSB AAYXX CITATION OVT NPM 7QL 7T5 7T7 7TK 7U9 8FD C1K FR3 H94 M7N P64 7X8 |
ID | FETCH-LOGICAL-c534t-f6fc6c21efcafa96e468b4c623113bc99563de86af408db3913678607c0517633 |
ISSN | 1344-6304 1884-2836 |
IngestDate | Fri Jul 11 10:18:24 EDT 2025 Mon Jun 30 12:03:42 EDT 2025 Thu Jan 02 22:57:45 EST 2025 Tue Jul 01 03:55:16 EDT 2025 Thu Apr 24 23:04:39 EDT 2025 Thu Aug 17 20:33:00 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | COVID-19 New York fungal infection intensive care unit invasive mechanical ventilation bacterial infection steroid |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c534t-f6fc6c21efcafa96e468b4c623113bc99563de86af408db3913678607c0517633 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/yoken/74/4/74_JJID.2020.884/_article/-char/en |
PMID | 33390434 |
PQID | 2557260141 |
PQPubID | 2048383 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2475087090 proquest_journals_2557260141 pubmed_primary_33390434 crossref_citationtrail_10_7883_yoken_JJID_2020_884 crossref_primary_10_7883_yoken_JJID_2020_884 jstage_primary_article_yoken_74_4_74_JJID_2020_884_article_char_en |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021/07/31 |
PublicationDateYYYYMMDD | 2021-07-31 |
PublicationDate_xml | – month: 07 year: 2021 text: 2021/07/31 day: 31 |
PublicationDecade | 2020 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan – name: Tokyo |
PublicationTitle | Japanese Journal of Infectious Diseases |
PublicationTitleAlternate | Jpn J Infect Dis |
PublicationYear | 2021 |
Publisher | National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee Japan Science and Technology Agency |
Publisher_xml | – name: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee – name: Japan Science and Technology Agency |
References | 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. 20. Tanne JH. Covid-19: New York City deaths pass 1000 as Trump tells Americans to distance for 30 days. BMJ. 2020;369:m1333. 11. Jangi S. Facing uncertainty--dispatch from Beth Israel Medical Center, Manhattan. N Engl J Med. 2012;367:2267-9. 3. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606. 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. 9. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed September 14, 2020. 17. Capecchi PL, Lazzerini PE, Volterrani L, et al. Antirheumatic agents in covid-19: is IL-6 the right target? Ann Rheum Dis. 2021;80:e2. 21. Murakami N, Siktel HB, Lucido D, et al. Disaster preparedness and awareness of patients on hemodialysis after Hurricane Sandy. Clin J Am Soc Nephrol. 2015;10:1389-96. 10. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020;ciaa478. 27. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307-16. 2. Religions for Peace. Coronavirus COVID-19 global cases by the Center for Systems Science and Enginerring at Johns Hopkins University. Available at <https://www.rfp.org/resources/coronavirus-covid-19-global-cases-by-the-center-for-systems-science-and-engineering-csse-at-johns-hopkins-university-jhu/>. Accessed April 27, 2021. 14. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:56:105949. 18. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92:2283-5. 7. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-43. 8. The RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19 - preliminary report. N Engl J Med. 2021;384:693-704. 25. The Writing Committee for the REMAP-CAP Investigators; Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317-29. 5. Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020;26:948 e1-948 e3. 12. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-10. 22. Berlin DA, Gulick RM, Martinez FJ. Severe covid-19. N Engl J Med. 2020;383:2451-60. 23. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-5. 26. Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298-1306. 19. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574-81. 6. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18. 24. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757-67. 13. Hartikainen TS, Sörensen NA, Haller PM, et al. Clinical application of the 4th universal definition of myocardial infarction. Eur Heart J. 2020;41:2209-16. 4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. 16. Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming covid-19 pneumonia. BMJ. 2020;370:m2426. 22 23 24 25 26 27 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21 |
References_xml | – reference: 22. Berlin DA, Gulick RM, Martinez FJ. Severe covid-19. N Engl J Med. 2020;383:2451-60. – reference: 7. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-43. – reference: 17. Capecchi PL, Lazzerini PE, Volterrani L, et al. Antirheumatic agents in covid-19: is IL-6 the right target? Ann Rheum Dis. 2021;80:e2. – reference: 6. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18. – reference: 12. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-10. – reference: 21. Murakami N, Siktel HB, Lucido D, et al. Disaster preparedness and awareness of patients on hemodialysis after Hurricane Sandy. Clin J Am Soc Nephrol. 2015;10:1389-96. – reference: 25. The Writing Committee for the REMAP-CAP Investigators; Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317-29. – reference: 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. – reference: 2. Religions for Peace. Coronavirus COVID-19 global cases by the Center for Systems Science and Enginerring at Johns Hopkins University. Available at <https://www.rfp.org/resources/coronavirus-covid-19-global-cases-by-the-center-for-systems-science-and-engineering-csse-at-johns-hopkins-university-jhu/>. Accessed April 27, 2021. – reference: 5. Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020;26:948 e1-948 e3. – reference: 19. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574-81. – reference: 8. The RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19 - preliminary report. N Engl J Med. 2021;384:693-704. – reference: 9. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed September 14, 2020. – reference: 26. Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298-1306. – reference: 23. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-5. – reference: 13. Hartikainen TS, Sörensen NA, Haller PM, et al. Clinical application of the 4th universal definition of myocardial infarction. Eur Heart J. 2020;41:2209-16. – reference: 4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. – reference: 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. – reference: 20. Tanne JH. Covid-19: New York City deaths pass 1000 as Trump tells Americans to distance for 30 days. BMJ. 2020;369:m1333. – reference: 3. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606. – reference: 18. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92:2283-5. – reference: 10. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020;ciaa478. – reference: 11. Jangi S. Facing uncertainty--dispatch from Beth Israel Medical Center, Manhattan. N Engl J Med. 2012;367:2267-9. – reference: 27. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307-16. – reference: 14. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:56:105949. – reference: 16. Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming covid-19 pneumonia. BMJ. 2020;370:m2426. – reference: 24. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757-67. – ident: 2 – ident: 19 doi: 10.1001/jama.2020.5394 – ident: 15 doi: 10.1016/S0140-6736(20)30566-3 – ident: 3 doi: 10.1136/bmj.m606 – ident: 24 doi: 10.1164/rccm.201706-1172OC – ident: 4 doi: 10.1016/S0140-6736(20)30183-5 – ident: 7 doi: 10.1001/jamainternmed.2020.0994 – ident: 12 doi: 10.1001/jama.2016.0287 – ident: 26 doi: 10.1001/jama.2020.16761 – ident: 18 doi: 10.1002/jmv.25948 – ident: 9 – ident: 16 doi: 10.1136/bmj.m2426 – ident: 21 doi: 10.2215/CJN.10181014 – ident: 22 doi: 10.1056/NEJMcp2009575 – ident: 8 doi: 10.1056/NEJMoa2021436 – ident: 20 doi: 10.1136/bmj.m1333 – ident: 6 doi: 10.1038/s41392-020-0127-9 – ident: 13 doi: 10.1093/eurheartj/ehaa035 – ident: 14 doi: 10.1016/j.ijantimicag.2020.105949 – ident: 17 doi: 10.1136/annrheumdis-2020-217523 – ident: 1 doi: 10.1056/NEJMoa2001017 – ident: 27 doi: 10.1001/jama.2020.17021 – ident: 5 doi: 10.1016/j.cmi.2020.04.040 – ident: 11 doi: 10.1056/NEJMp1213844 – ident: 10 doi: 10.1093/cid/ciaa478 – ident: 23 doi: 10.1016/S0140-6736(20)30317-2 – ident: 25 |
SSID | ssj0025510 |
Score | 2.4548402 |
Snippet | Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus... Since cytokine release syndrome is considered to be associated with severe cases of COVID-19, steroids are expected to be effective for its treatment. We aimed... |
SourceID | proquest pubmed crossref jstage |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 307 |
SubjectTerms | Bacterial diseases bacterial infection Bacterial infections Confidence intervals Coronaviruses COVID-19 Cytokines Dimers Eardrum fungal infection Fungi Hypertension Infections Inflammation L-Lactate dehydrogenase Lactate dehydrogenase Lactic acid Mortality Patients Secondary infection Statistical analysis steroid Steroid hormones Steroids Vascular diseases Viral diseases |
Title | Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City |
URI | https://www.jstage.jst.go.jp/article/yoken/74/4/74_JJID.2020.884/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/33390434 https://www.proquest.com/docview/2557260141 https://www.proquest.com/docview/2475087090 |
Volume | 74 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Japanese Journal of Infectious Diseases, 2021/07/31, Vol.74(4), pp.307-315 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKQNNeEL8pDGQk3kZGEjtO8ggtsBVGJdSh8hTZTkLDRjMt6QP767lLYreROgS8RFFsx9Hdd_adc_5MyEsZRMgKljtuJLnDtXId6UrMmdJhpLgIVLM0cPJZHJ3yyTyYDwafNrKWVrU61Fdb95X8j1bhGegVd8n-g2btS-EB3IN-4Qoahutf6RiMG3PKwWesMK5NMQPOZFc1GYyj6dfjsePFhj61ahPLTco5kiSURZsSa_mbRkXd-9U7gekUj6nsk0y0nawq84fHuuZTJY1DWhR6UVyW60XvLG1KZlldrdbPx9M2uX5xXsiDL8WV3Tv0cdWcC34wK6tFcVZsLlD4nln5xPmlHVSjiDvgxohtQzaE4Egd8as8y5aHk8nxGGJ23wVN883aIPeLn40WGWOxy7sF0D5Ttim6QW76EDTgeRYf5jbhB2Inz215p7DP11t63CO75h09N-XWD_DUv2fXByGNMzK7Q253UQR900LiLhlky3tk96TLk7hPvllkUIsMapEBd9Qggxpk0A4ZFJFBDTKwKiCDIjIoIuMBOX3_bjY6crpDNBwdMF47uci10L6X5VrmMhYZF2CDGrxez2NK48ZmlmaRkDl3o1SxGDn8IuGGGtnbBGMPyc6yXGaPCYXmQRiylOtYQlgeytBTyg8VRBhMxEE6JL6RWaI7hnk86OQ8gUgTZZ40Mk9Q5gnKPAGZD8kr2-iiJVj5c_W3rTJs5c76usohTzheeo1sHdzJCAPHkOwbRSad7VQJ4CNEfj3uDckLWwyDLf5BAzsDk0p8Dg42zHCxOySPWgDY7zDIeXJtyVOyt7aPfbJTX66yZ-DS1up5g9TfxQqglQ |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+secondary+infection+in+COVID-19+patients+treated+with+steroids+in+New+York+City&rft.jtitle=Japanese+journal+of+infectious+diseases&rft.au=Obata%2C+Reiichiro&rft.au=Maeda%2C+Tetsuro&rft.au=DO%2C+Dahlia+Rizk&rft.au=Kuno%2C+Toshiki&rft.date=2021-07-31&rft.eissn=1884-2836&rft_id=info:doi/10.7883%2Fyoken.JJID.2020.884&rft_id=info%3Apmid%2F33390434&rft.externalDocID=33390434 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1344-6304&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1344-6304&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1344-6304&client=summon |